Modified Placental Tissue for Non-Cardiovascular Angiogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Suitable neovascularization remains an unresolved issue hampering the progress of regenerative medicine, wound healing, and treatment of non-cardiovascular conditions, as conventional therapies lack effective vasculature for oxygen, nutrient supply, and metabolic product evacuation.
Innovation Solution
A method involving the delivery of modified placental tissue or placental growth factors and stem cells to non-cardiovascular body regions to induce angiogenesis, using compositions such as micronized modified placental tissue or extracts, which can be administered via injection or nebulization to promote blood flow and tissue regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional regenerative therapies are used, then tissue repair and regeneration are attempted, but suitable neovascularization is lacking which hampers the progress of treatment
Solution Approach 1:
The patent uses modified placental tissue as an intermediary substance that delivers pro-angiogenic factors to the target tissue. This intermediary approach resolves the contradiction by providing a vehicle that specifically addresses the vasculature deficiency without requiring complex engineered vascular structures, thereby enabling conventional regenerative therapies to function effectively.
Solution Approach 2:
The patent modifies placental tissue through processing steps that enhance its pro-angiogenic properties. By changing the physical and biochemical parameters of the placental tissue (such as micronization, dehydration, or cross-linking), the therapy achieves reliable tissue regeneration by optimizing the vasculature-inducing capability of the biomaterial.
2Reliability
If modified placental tissue is delivered to induce angiogenesis, then blood flow and tissue regeneration are improved, but the complexity of the treatment method increases
Solution Approach 1:
The modified placental tissue serves multiple functions simultaneously: it acts as a delivery vehicle for pro-angiogenic factors, provides a scaffold for tissue regeneration, and stimulates blood vessel formation. This multi-functionality resolves the contradiction by achieving reliable angiogenesis induction through a single versatile treatment approach rather than multiple separate interventions.
3Reliability
If placental growth factors and stem cells are extracted and delivered, then neovascularization is promoted, but the manufacturing process becomes more complex
Solution Approach 1:
The patent extracts placental growth factors and stem cells from placental tissue to create a concentrated therapeutic composition. This extraction approach resolves the contradiction by isolating the active neovascularization-promoting components, thereby enhancing treatment reliability while allowing the final product to be manufactured through standardized extraction and formulation processes.
Data Source
AI summary
Disclosed herewith is a method for inducing angiogenesis using modified placental tissue or an extract thereof to treat conditions other than cardiovascular conditions.